Global HIV Vaccine Market & Clinical Trial Outlook to 2022 - Key Vendors are AlphaVax, GeneCure & FIT Biotech - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global HIV Vaccine Market & Clinical Trial Outlook 2022" report to their offering.

Worldwide, around 35 Million people are currently infected with the HIV and about 30 Million people died because of the AIDS infection since the beginning of the epidemic. There is no human example of clearing an HIV infection naturally. The HIV virus makes copies of it very quickly; many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways of immune system which needs to respond against the HIV infection.

Vaccines are among the most powerful and cost-effective disease prevention tools. A vaccine that could prevent the HIV infection or stop the development of the disease would greatly support in the fight against the AIDS disease. Vaccines have been crucial in worldwide smallpox elimination efforts, have nearly eliminated polio and have drastically reduced the incidence of infectious diseases like measles and pertussis in the US.

However, the question is arising of whether a HIV vaccine should be developed for a single strain or if it should be designed for varied strain structures. The whole aim is to provide better medication for the eradication of the virus by any means.

Companies Mentioned:

  • AlphaVax
  • Antigen Express
  • Argo Therapeutics
  • Bionor Pharmaceuticals
  • Celldex Therapeutics
  • Crucell Pharmaceutical
  • FIT Biotech
  • GeneCure
  • Genetic Immunity
  • GenVec
  • GeoVax Labs
  • Glaxo Smithkline
  • Immune Response BioPharma
  • Inovio Pharmaceuticals
  • Novartis
  • Oncolys Biopharma
  • PaxVax
  • Profectus Biosciences
  • Sanofi
  • TVAX Biomedical

Key Topics Covered:

1. Introduction to Human Immunodeficiency Virus (HIV) Vaccines

2. Need for the Development of HIV Vaccine

3. Primer of HIV inside the Body

4. HIV Vaccine Development Process

5. Modified Approaches for HIV Vaccine Development

6. Prophylactic & Therapeutic HIV Vaccine

7. HIV Drugs Taxonomy & Resistance

8. Decisive Factors for Commercialization of HIV Vaccines

9. Global HIV Vaccine Market Outlook

10. Global HIV Vaccine Clinical Pipeline Overview

11. Global HIV Vaccine Market Dynamics

12. Global HIV Vaccine Market Future Outlook

13. Global HIV Vaccine Clinical Pipeline by Company, Indication & Phase

14. Competitive Landscape

For more information about this report visit http://www.researchandmarkets.com/research/6nlrp3/global_hiv

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Clinical Trials, Vaccines

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Clinical Trials, Vaccines